Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.58 |
| ▸ | CES2 | O00748 | 1/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.58 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | FNTA | P49354 | 1/20 | 0.48 |
| ▸ | FNTB | P49356 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | PAM | P19021 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14997451 | 0.84 | CA2 (0.58) | AKR1B1MEN1KMT2AHIF1AALDH1A1 | |
| SCHEMBL699924 | 0.83 | CES1 (0.61) | CES1CES2AKR1B1CTBP2MEN1 | |
| SCHEMBL1300068 | 0.79 | CES1 (0.56) | CES1CES2AKR1B1CTBP2MEN1 | |
| SCHEMBL15241380 | 0.79 | CES1 (0.56) | CES1CES2AKR1B1CTBP2MEN1 | |
| SCHEMBL15372403 | 0.77 | CES2 (0.44) | CES1CES2AKR1B1CTBP2FNTA | |
| SCHEMBL7431387 | 0.77 | CYP19A1 (0.46) | ALDH1A1GAAHTTMAPTMET | |
| SCHEMBL16519727 | 0.77 | KEAP1 (0.61) | KMT2AHDAC8HDAC6ALDH1A1MAPK1 | |
| SCHEMBL8013340 | 0.77 | CES1 (0.54) | CES1CES2AKR1B1CTBP2MEN1 | |
| SCHEMBL13017398 | 0.77 | CTBP2 (0.53) | CTBP2MEN1KMT2AHDAC8HDAC6 | |
| SCHEMBL17040103 | 0.77 | GFER (0.42) | ALDH1A1TSHRCYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988665-B2 | Methods for determining protein binding specificity using peptide libraries | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2018-06-05 | — | — | US | disclosed |
| EP-2328865-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-31 | — | — | EP | disclosed |
| CN-103596929-B | Pyrazole and pyrimidine tricycloalkenones as antioxidant inflammation modulators | 里亚塔医药公司 | 2016-10-19 | — | — | CN | disclosed |
| US-20160115145-A1 | ROSEOBACTICIDES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-04-28 | — | — | US | disclosed |
| WO-2015071493-A1 | CHEMOENZYMATIC SYNTHESIS OF THE CEPHALOSPORINE INTERMEDIATE 7-AMINO-3-ALKENYLCEPHEM-4-CARBOXYLIC ACID | SANDOZ AG (CH) | 2015-05-21 | — | — | WO | disclosed |
| WO-2013163466-A1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-10-31 | — | — | WO | disclosed |
| WO-2010055136-A1 | PROCESS FOR THE PURIFICATION OF ANTIBODIES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | NOVO NORDISK A/S (DK) | 2010-05-20 | — | — | WO | disclosed |
| EP-1091938-A2 | ANTIHISTAMINIC PIPERIDINE DERIVATIVES AND INTERMEDIATES FOR THE PREPARATION THEREOF | Aventis Pharmaceuticals Inc. (US) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001671-A2 | ANTIHISTAMINIC PIPERIDINE DERIVATIVES AND INTERMEDIATES FOR THE PREPARATION THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115145-A1 | ROSEOBACTICIDES AND USES THEREOF | CROCC, MRPL21, RPL41 | CES1 4119/4885CES2 420/4885AKR1B1 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.